Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.040
+0.020 (1.96%)
At close: Oct 5, 2026, 4:00 PM EDT
1.040
0.00 (0.00%)
Pre-market: Oct 6, 2026, 4:00 AM EDT
Metagenomi Therapeutics Revenue
Metagenomi Therapeutics had revenue of $-257.00K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $13.56M, down -59.84% year-over-year. In the year 2025, Metagenomi Therapeutics had annual revenue of $25.21M, down -51.79%.
Revenue (ttm)
$13.56M
Revenue Growth
-59.84%
P/S Ratio
2.91
Revenue / Employee
$120,009
Employees
113
Market Cap
39.29M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 25.21M | -27.09M | -51.79% |
| Dec 31, 2024 | 52.30M | 7.54M | 16.84% |
| Dec 31, 2023 | 44.76M | 27.56M | 160.21% |
| Dec 31, 2022 | 17.20M | 16.96M | 6,978.19% |
| Dec 31, 2021 | 243.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Actinium Pharmaceuticals | 35.09M |
| Aligos Therapeutics | 31.52M |
| Werewolf Therapeutics | 21.00M |
| Veru Inc. | 16.89M |
| Impact BioMedical | 35.00K |
MGX News
- 25 days ago - Metagenomi Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 weeks ago - Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PRNewsWire
- 7 weeks ago - Metagenomi price target lowered to $7 from $9 at Wells Fargo - TheFly
- 1 month ago - Metagenomi Therapeutics Quarterly report: Q2 2026 - Filings
- 1 month ago - Metagenomi Therapeutics Earnings release: Q2 2026 - Filings
- 2 months ago - Prolynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease Portfolio - GlobeNewsWire
- 3 months ago - Metagenomi transferred with a Buy at Chardan - TheFly